ArticleFrontiers in neurology2021
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis.
Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 34 citations in OpenAlex.
- Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.Journal of neurology · 2023Trial
- Innovative Clinical Pharmacology, Modeling, and Simulation Strategies for Accelerating Rare Disease Drug Development.Journal of clinical pharmacology · 2026Review
- Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non-Japanese Individuals.Journal of clinical pharmacology · 2026Review
- Clinical Management of Antirheumatic Drug Exposure During Therapeutic Plasma Exchange.Clinical reviews in allergy & immunology · 2026Review
- Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab.Annals of clinical and translational neurology · 2026Article
- Italian recommendations for the diagnosis and treatment of myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Emergency use of eculizumab in impending and manifest myasthenic crisis: a retrospective case series.Therapeutic advances in neurological disorders · 2026Article
- Clinical study of eculizumab with or with not tacrolimus in the treatment of generalized myasthenia gravis.Frontiers in immunology · 2026Article
- Data-augmented machine learning refines the effective-concentration estimate for eculizumab in complement-mediated diseases.Frontiers in immunology · 2026Article
- Article
- Therapeutic strategies targeting complement in myasthenia gravis patients.Journal of neurology · 2025Review
- Review
- Eculizumab as fast-acting rescue therapy for pembrolizumab-induced impending crisis state of myasthenia gravis: a case report.Therapeutic advances in neurological disorders · 2025Article
- Case Report: Eculizumab in highly active myasthenia gravis complicated by severe infections.Frontiers in immunology · 2025Article
- The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases.Pharmaceutics · 2024Review
- Targeted Treatments for Myasthenia Gravis in Children and Adolescents.Paediatric drugs · 2024Review
- Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS- real-world data.BMC nephrology · 2024Article
- Eculizumab as Additional Rescue Therapy in Myasthenic Crisis.Muscles (Basel, Switzerland) · 2024Article
- Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study.Therapeutic advances in neurological disorders · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.